Aptevo Therapeutics, Inc. (APVO)

Aptevo Therapeutics' stock price has been impacted by several events. In December 2025, the company announced a 1-for-18 reverse stock split. In January 2026, Aptevo secured a $60 million equity line of credit. In February 2026, the company announced executive leadership transitions. In March 2026, Aptevo reported positive interim clinical trial results for mipletamig, but the stock price fell. Aptevo also reported a net loss of $27.5 million for 2025. The share price experienced a significant decline of 84.21% between April 7, 2025, and April 2, 2026.

Aptevo Therapeutics Inc. is a clinical-stage biotechnology company, and the demand for its products is not subject to typical consumer-driven seasonality. There is no discernible demand seasonality for Aptevo Therapeutics' products and services in the traditional sense.

Aptevo Therapeutics, Inc. is a clinical-stage biotechnology company specializing in immuno-oncology and hematology therapeutics. The company develops bispecific and multi-specific antibody-based therapies using its ADAPTIR™ and ADAPTIR-FLEX™ platforms. Its major product candidates include Mipletamig, a bispecific antibody in Phase 1b/2 clinical trials for AML and MDS, ALG.APV-527, a bispecific conditional 4-1BB agonist co-developed with Alligator Bioscience, APVO451 and APVO452, trispecific T-cell engagers targeting solid tumors and prostate cancer respectively, and preclinical candidates APVO711, APVO0442, and APVO603.

Aptevo Therapeutics Inc. is headquartered in Seattle, Washington, and is incorporated in Delaware. The company's primary focus for developing immunotherapeutic candidates is within the United States.

Information directly addressing Aptevo Therapeutics' brand reputation is not explicitly available. The company's reputation is reflected through its clinical trial progress, financial performance, and stock market activity. Positive clinical trial results for mipletamig were reported, but the subsequent drop in stock price suggests investor confidence may be influenced by broader concerns. Executive leadership transitions and securing an equity line of credit could be viewed positively.

Aptevo Therapeutics' ownership includes institutional, retail, and individual investors. Retail investors hold a substantial portion of the stock, approximately 96.70%. Institutional ownership varies across reports. Insiders own about 1.15% of the company's stock. Major institutional shareholders include Vanguard Group Inc, Citigroup Inc, Advisor Group Holdings, Inc., UBS Group AG, Tower Research Capital LLC (TRC), SBI Securities Co., Ltd., Tradewinds Capital Management, LLC, Bank Of America Corp /de/, Fmr Llc, Cwm, Llc, Armistice Capital LLC, Virtu Financial LLC, Birchview Capital LP, and Point72 Asset Management, L.P.. Grant Grady III owns the most shares among individual investors.